Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies.
Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA. Kristensen LE, et al. Among authors: mease pj. Ther Adv Musculoskelet Dis. 2024 Nov 11;16:1759720X241288071. doi: 10.1177/1759720X241288071. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 39534481 Free PMC article.
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.
Østergaard M, Boesen M, Maksymowych WP, Lambert RG, Bubb MR, Kubassova O, Valenzuela G, Reddy J, Colgan S, Klyachkin Y, Deignan C, Zhou Z, Amouzadeh H, Mease PJ. Østergaard M, et al. Among authors: mease pj. Lancet Rheumatol. 2024 Oct 30:S2665-9913(24)00232-7. doi: 10.1016/S2665-9913(24)00232-7. Online ahead of print. Lancet Rheumatol. 2024. PMID: 39488216
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.
Navarro-Compán V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A. Navarro-Compán V, et al. Among authors: mease pj. J Rheumatol. 2024 Oct 15:jrheum.2024-0223. doi: 10.3899/jrheum.2024-0223. Online ahead of print. J Rheumatol. 2024. PMID: 39406403 Free article.
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.
Mease PJ, Baraliakos X, Chandran V, Soriano ER, Nash P, Deodhar A, Rampakakis E, Shiff NJ, Chakravarty SD, Shawi M, Merola JF, McInnes IB. Mease PJ, et al. ACR Open Rheumatol. 2024 Oct 4. doi: 10.1002/acr2.11732. Online ahead of print. ACR Open Rheumatol. 2024. PMID: 39365294 Free article.
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
Husni ME, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Husni ME, et al. Among authors: mease pj. RMD Open. 2024 Sep 23;10(3):e004464. doi: 10.1136/rmdopen-2024-004464. RMD Open. 2024. PMID: 39313302 Free PMC article. Clinical Trial.
712 results